Search Results - "Ron, Bose"

Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study by Hainsworth, John D, Meric-Bernstam, Funda, Swanton, Charles, Hurwitz, Herbert, Spigel, David R, Sweeney, Christopher, Burris, Howard, Bose, Ron, Yoo, Bongin, Stein, Alisha, Beattie, Mary, Kurzrock, Razelle

“…Purpose Detection of specific molecular alterations in tumors guides the selection of effective targeted treatment of patients with several types of cancer…”
Get full text

Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study by Meric-Bernstam, Funda, Hurwitz, Herbert, Raghav, Kanwal Pratap Singh, McWilliams, Robert R, Fakih, Marwan, VanderWalde, Ari, Swanton, Charles, Kurzrock, Razelle, Burris, Howard, Sweeney, Christopher, Bose, Ron, Spigel, David R, Beattie, Mary S, Blotner, Steven, Stone, Alyssa, Schulze, Katja, Cuchelkar, Vaikunth, Hainsworth, John

“…Therapies targeting HER2 have improved clinical outcomes in HER2-positive breast and gastric cancers, and are emerging as potential treatments for…”
Get full text

Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study by Javle, Milind, Borad, Mitesh J, Azad, Nilofer S, Kurzrock, Razelle, Abou-Alfa, Ghassan K, George, Ben, Hainsworth, John, Meric-Bernstam, Funda, Swanton, Charles, Sweeney, Christopher J, Friedman, Claire F, Bose, Ron, Spigel, David R, Wang, Yong, Levy, Jonathan, Schulze, Katja, Cuchelkar, Vaikunth, Patel, Arisha, Burris, Howard

“…Systemic therapies for metastatic biliary tract cancers are few, and patients have a median overall survival of less than 1 year. MyPathway evaluates the…”
Get full text

CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer by Griffith, Malachi, Spies, Nicholas C, Krysiak, Kilannin, McMichael, Joshua F, Coffman, Adam C, Danos, Arpad M, Ainscough, Benjamin J, Ramirez, Cody A, Rieke, Damian T, Kujan, Lynzey, Barnell, Erica K, Wagner, Alex H, Skidmore, Zachary L, Wollam, Amber, Liu, Connor J, Jones, Martin R, Bilski, Rachel L, Lesurf, Robert, Feng, Yan-Yang, Shah, Nakul M, Bonakdar, Melika, Trani, Lee, Matlock, Matthew, Ramu, Avinash, Campbell, Katie M, Spies, Gregory C, Graubert, Aaron P, Gangavarapu, Karthik, Eldred, James M, Larson, David E, Walker, Jason R, Good, Benjamin M, Wu, Chunlei, Su, Andrew I, Dienstmann, Rodrigo, Margolin, Adam A, Tamborero, David, Lopez-Bigas, Nuria, Jones, Steven J M, Bose, Ron, Spencer, David H, Wartman, Lukas D, Wilson, Richard K, Mardis, Elaine R, Griffith, Obi L

“…CIViC is an expert-crowdsourced knowledgebase for Clinical Interpretation of Variants in Cancer describing the therapeutic, prognostic, diagnostic and…”
Get full text

Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers by Govindan, Ramaswamy, Ding, Li, Griffith, Malachi, Subramanian, Janakiraman, Dees, Nathan D., Kanchi, Krishna L., Maher, Christopher A., Fulton, Robert, Fulton, Lucinda, Wallis, John, Chen, Ken, Walker, Jason, McDonald, Sandra, Bose, Ron, Ornitz, David, Xiong, Donghai, You, Ming, Dooling, David J., Watson, Mark, Mardis, Elaine R., Wilson, Richard K.

“…We report the results of whole-genome and transcriptome sequencing of tumor and adjacent normal tissue samples from 17 patients with non-small cell lung…”
Get full text

HER2 activating mutations are targets for colorectal cancer treatment by Kavuri, Shyam M, Jain, Naveen, Galimi, Francesco, Cottino, Francesca, Leto, Simonetta M, Migliardi, Giorgia, Searleman, Adam C, Shen, Wei, Monsey, John, Trusolino, Livio, Jacobs, Samuel A, Bertotti, Andrea, Bose, Ron

“…The Cancer Genome Atlas project identified HER2 somatic mutations and gene amplification in 7% of patients with colorectal cancer. Introduction of the HER2…”
Get more information

Genomic Characterization of Primary Invasive Lobular Breast Cancer by Desmedt, Christine, Zoppoli, Gabriele, Gundem, Gunes, Pruneri, Giancarlo, Larsimont, Denis, Fornili, Marco, Fumagalli, Debora, Brown, David, Rothé, Françoise, Vincent, Delphine, Kheddoumi, Naima, Rouas, Ghizlane, Majjaj, Samira, Brohée, Sylvain, Van Loo, Peter, Maisonneuve, Patrick, Salgado, Roberto, Van Brussel, Thomas, Lambrechts, Diether, Bose, Ron, Metzger, Otto, Galant, Christine, Bertucci, François, Piccart-Gebhart, Martine, Viale, Giuseppe, Biganzoli, Elia, Campbell, Peter J, Sotiriou, Christos

“…Invasive lobular breast cancer (ILBC) is the second most common histologic subtype after invasive ductal breast cancer (IDBC). Despite clinical and pathologic…”
Get full text

Activating HER2 mutations in HER2 gene amplification negative breast cancer by Bose, Ron, Kavuri, Shyam M, Searleman, Adam C, Shen, Wei, Shen, Dong, Koboldt, Daniel C, Monsey, John, Goel, Nicholas, Aronson, Adam B, Li, Shunqiang, Ma, Cynthia X, Ding, Li, Mardis, Elaine R, Ellis, Matthew J

“…Data from 8 breast cancer genome-sequencing projects identified 25 patients with HER2 somatic mutations in cancers lacking HER2 gene amplification. To…”
Get more information

Whole-genome analysis informs breast cancer response to aromatase inhibition by Ellis, Matthew J., Ding, Li, Shen, Dong, Luo, Jingqin, Suman, Vera J., Wallis, John W., Van Tine, Brian A., Hoog, Jeremy, Goiffon, Reece J., Goldstein, Theodore C., Ng, Sam, Lin, Li, Crowder, Robert, Snider, Jacqueline, Ballman, Karla, Weber, Jason, Chen, Ken, Koboldt, Daniel C., Kandoth, Cyriac, Schierding, William S., McMichael, Joshua F., Miller, Christopher A., Lu, Charles, Harris, Christopher C., McLellan, Michael D., Wendl, Michael C., DeSchryver, Katherine, Allred, D. Craig, Esserman, Laura, Unzeitig, Gary, Margenthaler, Julie, Babiera, G. V., Marcom, P. Kelly, Guenther, J. M., Leitch, Marilyn, Hunt, Kelly, Olson, John, Tao, Yu, Maher, Christopher A., Fulton, Lucinda L., Fulton, Robert S., Harrison, Michelle, Oberkfell, Ben, Du, Feiyu, Demeter, Ryan, Vickery, Tammi L., Elhammali, Adnan, Piwnica-Worms, Helen, McDonald, Sandra, Watson, Mark, Dooling, David J., Ota, David, Chang, Li-Wei, Bose, Ron, Ley, Timothy J., Piwnica-Worms, David, Stuart, Joshua M., Wilson, Richard K., Mardis, Elaine R.

“…To correlate the variable clinical features of oestrogen-receptor-positive breast cancer with somatic alterations, we studied pretreatment tumour biopsies…”
Get full text

Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer by Ma, Cynthia X, Bose, Ron, Gao, Feng, Freedman, Rachel A, Telli, Melinda L, Kimmick, Gretchen, Winer, Eric, Naughton, Michael, Goetz, Matthew P, Russell, Christy, Tripathy, Debu, Cobleigh, Melody, Forero, Andres, Pluard, Timothy J, Anders, Carey, Niravath, Polly Ann, Thomas, Shana, Anderson, Jill, Bumb, Caroline, Banks, Kimberly C, Lanman, Richard B, Bryce, Richard, Lalani, Alshad S, Pfeifer, John, Hayes, Daniel F, Pegram, Mark, Blackwell, Kimberly, Bedard, Philippe L, Al-Kateb, Hussam, Ellis, Matthew J C

“…Based on promising preclinical data, we conducted a single-arm phase II trial to assess the clinical benefit rate (CBR) of neratinib, defined as…”
Get full text

Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts by Li, Shunqiang, Shen, Dong, Shao, Jieya, Crowder, Robert, Liu, Wenbin, Prat, Aleix, He, Xiaping, Liu, Shuying, Hoog, Jeremy, Lu, Charles, Ding, Li, Griffith, Obi L., Miller, Christopher, Larson, Dave, Fulton, Robert S., Harrison, Michelle, Mooney, Tom, McMichael, Joshua F., Luo, Jingqin, Tao, Yu, Goncalves, Rodrigo, Schlosberg, Christopher, Hiken, Jeffrey F., Saied, Laila, Sanchez, Cesar, Giuntoli, Therese, Bumb, Caroline, Cooper, Crystal, Kitchens, Robert T., Lin, Austin, Phommaly, Chanpheng, Davies, Sherri R., Zhang, Jin, Kavuri, Megha Shyam, McEachern, Donna, Dong, Yi Yu, Ma, Cynthia, Pluard, Timothy, Naughton, Michael, Bose, Ron, Suresh, Rama, McDowell, Reida, Michel, Loren, Aft, Rebecca, Gillanders, William, DeSchryver, Katherine, Wilson, Richard K., Wang, Shaomeng, Mills, Gordon B., Gonzalez-Angulo, Ana, Edwards, John R., Maher, Christopher, Perou, Charles M., Mardis, Elaine R., Ellis, Matthew J.

“…To characterize patient-derived xenografts (PDXs) for functional studies, we made whole-genome comparisons with originating breast cancers representative of…”
Get full text

The prognostic effects of somatic mutations in ER-positive breast cancer by Griffith, Obi L., Spies, Nicholas C., Anurag, Meenakshi, Griffith, Malachi, Luo, Jingqin, Tu, Dongsheng, Yeo, Belinda, Kunisaki, Jason, Miller, Christopher A, Krysiak, Kilannin, Hundal, Jasreet, Ainscough, Benjamin J, Skidmore, Zachary L., Campbell, Katie, Kumar, Runjun, Fronick, Catrina, Cook, Lisa, Snider, Jacqueline E., Davies, Sherri, Kavuri, Shyam M., Chang, Eric C., Magrini, Vincent, Larson, David E., Fulton, Robert S, Liu, Shuzhen, Leung, Samuel, Voduc, David, Bose, Ron, Dowsett, Mitch, Wilson, Richard K., Nielsen, Torsten O., Mardis, Elaine R, Ellis, Matthew J.

“…Here we report targeted sequencing of 83 genes using DNA from primary breast cancer samples from 625 postmenopausal (UBC-TAM series) and 328 premenopausal…”
Get full text

Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface by Pickin, Kerry A, Jura, Natalia, Cole, Philip A, Bose, Ron, Kuriyan, John, Zhang, Xuewu

“…Members of the epidermal growth factor receptor family (EGFR/ERBB1, ERBB2/HER2, ERBB3/HER3 and ERBB4/HER4) are key targets for inhibition in cancer therapy…”
Get full text

Retrospective Analysis of Treatment Patterns and Effectiveness of Palbociclib and Subsequent Regimens in Metastatic Breast Cancer by Xi, Jing, Oza, Aabha, Thomas, Shana, Ademuyiwa, Foluso, Weilbaecher, Katherine, Suresh, Rama, Bose, Ron, Cherian, Mathew, Hernandez-Aya, Leonel, Frith, Ashley, Peterson, Lindsay, Luo, Jingqin, Krishnamurthy, Jairam, Ma, Cynthia X

“…Cyclin-dependent kinase (CDK) 4/6 inhibitors are now the standard of care for hormone receptor-positive (HR+), HER2-negative (HER-) metastatic breast cancer…”
Get more information

Sacituzumab-govitecan-induced severe acute tubulointerstitial nephritis requiring hemodialysis by Guarin, Geneva, Netzel, Audrey, Flores, Karen Marie, Cumpelik, Arun, Bose, Ron

“…Background Sacituzumab govitecan is an antibody-drug conjugate that is FDA approved for refractory metastatic triple-negative breast cancer. It targets the…”
Get full text

Analysis of somatic mutations across the kinome reveals loss-of-function mutations in multiple cancer types by Kumar, Runjun D., Bose, Ron

“…In this study we use somatic cancer mutations to identify important functional residues within sets of related genes. We focus on protein kinases, a…”
Get full text

Environmental impact improvements due to introducing automation into underground copper mines by Moreau, Kyle, Laamanen, Corey, Bose, Ron, Shang, Helen, Scott, John Ashley

“…A life-cycle assessment (LCA) model was developed to comparatively analyze the use of manual and automated mining equipment in underground copper mine sites…”
Get full text

Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti‐HER2 targeted therapies by Ross, Jeffrey S., Gay, Laurie M., Wang, Kai, Ali, Siraj M., Chumsri, Saranya, Elvin, Julia A., Bose, Ron, Vergilio, Jo‐Anne, Suh, James, Yelensky, Roman, Lipson, Doron, Chmielecki, Juliann, Waintraub, Stanley, Leyland‐Jones, Brian, Miller, Vincent A., Stephens, Philip J.

“…BACKGROUND Activating, nonamplification ERBB2 mutations (ERBB2mut) are not detected by immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH),…”
Get full text

Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer by Ademuyiwa, Foluso O., Chen, Ina, Luo, Jingqin, Rimawi, Mothaffar F., Hagemann, Ian S., Fisk, Bryan, Jeffers, Gejae, Skidmore, Zachary L., Basu, Anamika, Richters, Megan, Ma, Cynthia X., Weilbaecher, Katherine, Davis, Jennifer, Suresh, Rama, Peterson, Lindsay L., Bose, Ron, Bagegni, Nusayba, Rigden, Caron E., Frith, Ashley, Rearden, Timothy P., Hernandez-Aya, Leonel F., Roshal, Anna, Clifton, Katherine, Opyrchal, Mateusz, Akintola-Ogunremi, Olaronke, Lee, Byung Ha, Ferrando-Martinez, Sara, Church, Sarah E., Anurag, Meenakshi, Ellis, Matthew J., Gao, Feng, Gillanders, William, Griffith, Obi L., Griffith, Malachi

“…Purpose Patients with triple-negative breast cancer (TNBC) who do not achieve pathological complete response (pCR) following neoadjuvant chemotherapy have a…”
Get full text

Her4 and Her2/neu Tyrosine Kinase Domains Dimerize and Activate in a Reconstituted in Vitro System by Monsey, John, Shen, Wei, Schlesinger, Paul, Bose, Ron

“…Her4 (ErbB-4) and Her2/neu (ErbB-2) are receptor-tyrosine kinases belonging to the epidermal growth factor receptor (EGFR) family. Crystal structures of EGFR…”
Get full text